Phaseline

Companies › Mylan Pharmaceuticals

Mylan Pharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 3; Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MR-130A-01 transdermal system
Progestin-only contraceptive patch
–Phase 3Female ContraceptionMay 2027
MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)
Progestin-based ovulation inhibitor
–Phase 2ContraceptionNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07365904MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)Phase 2ContraceptionOtherNov 2026
NCT06672016MR-130A-01 transdermal systemPhase 3Female ContraceptionOtherMay 2027

From the company's SEC filings

Complete response letters from FDA

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Good Molecules Sirnaomics Healx Skingenix Huons Biopharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.